Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

Hajime Uno, Brian Claggett, Lü Tian et al. · Journal of Clinical Oncology · 2014 · 782 citations · Full text

Public Health, Biostatistics, Oncology +16

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Kyongsun Pak, Hajime Uno, Dae Hyun Kim et al. · JAMA Oncology · 2017 · 264 citations · Full text

Public Health, Biostatistics, Oncology +15

Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics

Biotechnology Law Report · 2007 · 198 citations

Medicine, Oncology, Pharmacology +14

Analysis of duration of response in oncology trials

Stuart H. Ellis, Kevin J. Carroll, Kristine Pemberton · Contemporary Clinical Trials · 2007 · 26 citations

Medicine, Biostatistics, Oncology +11